MA46690A - Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 - Google Patents
Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2Info
- Publication number
- MA46690A MA46690A MA046690A MA46690A MA46690A MA 46690 A MA46690 A MA 46690A MA 046690 A MA046690 A MA 046690A MA 46690 A MA46690 A MA 46690A MA 46690 A MA46690 A MA 46690A
- Authority
- MA
- Morocco
- Prior art keywords
- triazolo
- pyrimidine compounds
- pde2 inhibitors
- pde2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196936 | 2016-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46690A true MA46690A (fr) | 2019-09-11 |
Family
ID=57223577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046690A MA46690A (fr) | 2016-11-02 | 2017-10-31 | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11319321B2 (fr) |
| EP (1) | EP3535268B1 (fr) |
| JP (1) | JP7018944B2 (fr) |
| KR (1) | KR20190067788A (fr) |
| CN (1) | CN109890824B (fr) |
| AU (1) | AU2017353313C1 (fr) |
| BR (1) | BR112019008604A2 (fr) |
| CA (1) | CA3038913A1 (fr) |
| EA (1) | EA039847B1 (fr) |
| ES (1) | ES2912264T3 (fr) |
| MA (1) | MA46690A (fr) |
| MX (1) | MX2019005123A (fr) |
| WO (1) | WO2018083101A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108349979B (zh) | 2015-11-02 | 2021-04-09 | 詹森药业有限公司 | [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物 |
| CA3041412A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Derives de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2 |
| ES2855032T3 (es) * | 2016-11-02 | 2021-09-23 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
| WO2018083101A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Composés de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2 |
| JP2020509004A (ja) * | 2017-02-27 | 2020-03-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体 |
| CN115960101B (zh) * | 2022-12-30 | 2024-10-18 | 海南大学 | 7-氧代-4,5,6,7-四氢吡唑并吡啶酰胺类化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993000313A2 (fr) | 1991-06-27 | 1993-01-07 | Virginia Commonwealth University | Ligands de recepteurs sigma et leur utilisation |
| ATE346050T1 (de) | 1998-01-27 | 2006-12-15 | Aventis Pharma Inc | Substituierte oxoazaheterocyclyl faktor xa hemmer |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| CN100395236C (zh) | 2002-10-03 | 2008-06-18 | 沃泰克斯药物股份有限公司 | 用于治疗神经病的哌嗪和哌啶衍生物 |
| EP1644003A1 (fr) | 2003-06-04 | 2006-04-12 | Vernalis (Cambridge) Limited | Triazolo ´1,5-a!pyrimidines et leur utilisation en medecine |
| CA2531232A1 (fr) | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Derives de triazolopyrimidine en tant qu'inhibiteurs de glycogene synthase kinase 3 |
| CA2553160C (fr) | 2003-12-29 | 2010-09-28 | Banyu Pharmaceutical Co., Ltd. | Derive de benzimidazole substitue en position 2 par un groupe heteroaryle |
| JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| WO2006034341A2 (fr) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques |
| EP1812439B2 (fr) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| WO2007113136A1 (fr) | 2006-03-30 | 2007-10-11 | Basf Aktiengesellschaft | Utilisation de triazolopyrimidines substituées dans la lutte contre des champignons phytopathogènes |
| JP2007332061A (ja) | 2006-06-14 | 2007-12-27 | Nippon Kayaku Co Ltd | 新規ピラゾロ［１，５−ａ］ピリミジン誘導体及びその用途 |
| US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
| WO2008048914A1 (fr) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Composés qui modulent le récepteur cb2 |
| US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP2010065024A (ja) * | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| ES2650744T3 (es) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
| AP2013007070A0 (en) | 2011-02-23 | 2013-08-31 | Pfizer | Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders |
| EP2723744B1 (fr) | 2011-06-27 | 2016-03-23 | Janssen Pharmaceutica, N.V. | Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]-quinoxaline |
| US9682953B2 (en) | 2011-09-23 | 2017-06-20 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| WO2015130905A1 (fr) | 2014-02-27 | 2015-09-03 | Merck Patent Gmbh | Composés hétérocycliques en tant qu'inhibiteurs du canal nav, et leurs utilisations |
| PL3119772T3 (pl) | 2014-03-19 | 2019-11-29 | Boehringer Ingelheim Int | Heteroarylowe inhibitory SYK |
| EP3134413B1 (fr) * | 2014-04-23 | 2019-09-11 | Dart NeuroScience (Cayman) Ltd. | Composés de [1,2,4]triazolo[1,5-a]pyrimidin-7-yle substitués utilisables en tant qu'inhibiteurs de pde2 |
| AP2016009464A0 (en) | 2014-04-25 | 2016-09-30 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands |
| CN105566321B (zh) | 2014-10-29 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| TWI530688B (zh) | 2014-11-18 | 2016-04-21 | 彭顯智 | 製備微奈米探針設備及方法 |
| CN105753817A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 一类取代氮杂环衍生物及其应用 |
| WO2016145614A1 (fr) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2 |
| WO2017000276A1 (fr) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2 |
| WO2017000277A1 (fr) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclo-composés de triazole substitués utilisés en tant qu'inhibiteurs de pde2 |
| CA3001857A1 (fr) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Composes, compositions et methodes d'utilisation contre des granules de stress |
| CN108349979B (zh) | 2015-11-02 | 2021-04-09 | 詹森药业有限公司 | [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物 |
| WO2017157882A1 (fr) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Inhibiteurs de la voie de biosynthèse de la sérine |
| CA3041412A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Derives de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2 |
| ES2855032T3 (es) | 2016-11-02 | 2021-09-23 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
| WO2018083101A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Composés de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2 |
| JP2020503300A (ja) | 2016-12-16 | 2020-01-30 | ヤンセン ファーマシューティカ エヌ．ベー． | 二環式ｏｇａ阻害剤化合物 |
-
2017
- 2017-10-31 WO PCT/EP2017/077918 patent/WO2018083101A1/fr unknown
- 2017-10-31 ES ES17797113T patent/ES2912264T3/es active Active
- 2017-10-31 MX MX2019005123A patent/MX2019005123A/es unknown
- 2017-10-31 MA MA046690A patent/MA46690A/fr unknown
- 2017-10-31 EA EA201991094A patent/EA039847B1/ru unknown
- 2017-10-31 JP JP2019523012A patent/JP7018944B2/ja active Active
- 2017-10-31 BR BR112019008604A patent/BR112019008604A2/pt active Search and Examination
- 2017-10-31 US US16/346,745 patent/US11319321B2/en active Active
- 2017-10-31 CN CN201780067757.4A patent/CN109890824B/zh not_active Expired - Fee Related
- 2017-10-31 EP EP17797113.2A patent/EP3535268B1/fr active Active
- 2017-10-31 AU AU2017353313A patent/AU2017353313C1/en not_active Ceased
- 2017-10-31 CA CA3038913A patent/CA3038913A1/fr active Pending
- 2017-10-31 KR KR1020197009775A patent/KR20190067788A/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EA039847B1 (ru) | 2022-03-18 |
| AU2017353313A1 (en) | 2019-04-18 |
| KR20190067788A (ko) | 2019-06-17 |
| MX2019005123A (es) | 2019-06-20 |
| EP3535268B1 (fr) | 2022-02-09 |
| JP2019532990A (ja) | 2019-11-14 |
| US11319321B2 (en) | 2022-05-03 |
| EA201991094A1 (ru) | 2019-09-30 |
| US20200055858A1 (en) | 2020-02-20 |
| WO2018083101A1 (fr) | 2018-05-11 |
| AU2017353313B2 (en) | 2021-09-16 |
| EP3535268A1 (fr) | 2019-09-11 |
| ES2912264T3 (es) | 2022-05-25 |
| JP7018944B2 (ja) | 2022-02-14 |
| BR112019008604A2 (pt) | 2019-07-09 |
| CN109890824A (zh) | 2019-06-14 |
| CA3038913A1 (fr) | 2018-05-11 |
| AU2017353313C1 (en) | 2022-06-09 |
| CN109890824B (zh) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53675A (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
| MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
| CL2019000942A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| FR22C1006I2 (fr) | Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak) | |
| DK3478682T3 (da) | [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser | |
| HK1259623A1 (zh) | 作爲irak4調節劑的吡唑並[1，5a]嘧啶衍生物 | |
| HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1，5-a]吡啶化合物 | |
| HK1245764A1 (zh) | 3-取代的5-氨基-6h-噻唑並[4，5-d]嘧啶-2，7-二酮化合物 | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| MA46690A (fr) | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 | |
| SG11201801365YA (en) | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | |
| DK3418281T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| MA43021A (fr) | Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1 | |
| MA52593A (fr) | 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1 | |
| ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
| ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
| EP3328840A4 (fr) | Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2 | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| EP3313852A4 (fr) | Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2 | |
| MA41174A (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
| DK3419979T3 (da) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser | |
| MA46463A (fr) | Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret | |
| TH1601003657A (th) | อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส |